BAY2586116

BAY2586116 is a novel small molecule drug developed as a nasal spray for the treatment of obstructive sleep apnea (OSA). It acts as an antagonist of TASK-1 and TASK-3 potassium channels (potassium channel subfamily K member 3 and 9), which are expressed on mechanoreceptors in the upper airway. By blocking these channels, BAY2586116 enhances the negative pressure reflex, leading to stronger activation of throat muscles during inspiration. This mechanism helps prevent narrowing or collapse of the upper airways during sleep—a key pathological factor in OSA. Clinical studies have shown that BAY2586116 can reduce OSA severity and lower next-day blood pressure in physiological responders, with no severe adverse events reported. The drug is being developed by Bayer and has reached Phase 2 clinical trials for obstructive sleep apnea[1][2][3][4][5][6][7].

Other names

TASK1/3 Inhibitor